Devonian Health Group announces the commercial launch of the Purgenesis(TM) Anti-aging treatment at the Canadian Dermatology Association’s annual conference

  • First launch of the Purgenesis™ skin care line
  • First and only product line distributed by dermatologists with the seal of the Canadian Dermatology Association’s Skin Health Program™

QUEBEC CITY, June 26, 2018 (GLOBE NEWSWIRE) -- Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSX VENTURE:GSD), a clinical stage botanical pharmaceutical corporation focused on developing a unique portfolio of botanical prescription drugs and cosmeceutical products, announced the official launch of its clinically proven Purgenesis™ Anti-aging treatment at the annual Canadian Dermatology Association’s conference held in Montreal on June 22nd, 2018.  

“We are excited to announce the launch of Purgenesis™ in Canada.” said Dr. André P. Boulet, the President and Chief Executive Officer of Devonian. “We believe this product is the answer to consumers searching for a clinically proven solution. The launch activities are managed by Devonian’s Commercial Division, Altius Healthcare Inc.” continued Dr. Boulet.

“Purgenesis™ is a skin care line that will be exclusively available from dermatologists and medical spas across Canada, and for good reason. Who else but medically trained skin care experts can appreciate the decades of research that has given life to the active complex that forms the basis of the Purgenesis™ skin care? The Purgenesis™ Anti-aging treatment is the first in an evolving line of cosmeceutical products. We are also proud that the Purgenesis™ Anti-aging treatment is the first product line distributed by dermatologists to be recognized by the Skin Health Program™ of the Canadian Dermatology Association.”, stated Sybil Dahan, President of Altius Healthcare.

About Purgenesis™ Anti-aging treatment

Purgenesis™ Anti-aging treatment has three components: a day cream, a night cream and an eye cream. These creams contain R-Spinasome®, a complex that is an active structure with anti-oxidant properties. The structure of this complex is critical to its function as an anti-oxidant, enabling it to capture and dissipate noxious energy generated by Reactive Oxygen Species (ROS), returning the complex to a state where it is ready to undergo new activation cycles. It is this dynamism and capacity to regenerate that provides R-Spinasome® with unprecedented, long-lasting anti-oxidant activity. A clinical study involving 72 subjects (aged 35-72years) was conducted to evaluate the performance of Purgenesis™ Anti-aging product line compared with two other leading prestige brands over a 28-day period of use. The results indicate that Purgenesis™ Anti-aging line is significantly superior than leading prestige brands in terms of its anti-wrinkle, firmness and hydration effects. Purgenesis™ Anti-aging treatment is patent-pending worldwide with the exception of Japan and Canada where patents were issued (#JP 5952261; #CDN 2,699,6765). The product has been recognized by the Canadian Dermatology Association’s Skin Health Program™.

About Devonian

Devonian Health Group Inc. is a late stage botanical pharmaceutical corporation with novel therapeutic approaches to targeting unmet medical needs. Devonian's core strategy is to develop prescription botanical drugs from plant materials and algae for the treatment of inflammatory-autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian’s focus is further supported by a US-FDA set of regulatory guidelines favouring a more efficient drug development pathway for prescription botanical drug products over those of traditional prescription medicines. Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings.  Devonian Health Group Inc. was incorporated in 2013 and is headquartered in Québec, Canada where it owns a state-of-the art extraction facility with full traceability ‘from the seed to the pill’. Their recently acquired commercialization partner, Altius Healthcare Inc., brings opportunities for further diversification and growth potential. Devonian is traded publicly on the TSXV Exchange (TSX VENTURE:GSD). 

For more information, visit

About Altius Healthcare Inc.

Based in Concord, Ontario, Altius Healthcare is a specialty pharmaceutical company with a primary focus of acquiring and in-licensing safe and innovative medicines and healthcare products designed to help people of all ages live healthier lives. Altius then leverages its expertise in the commercialisation activities required to successfully launch and distribute these medicines in Canada. The team’s diverse experience and expertise draws from nearly 40 years of producing, importing, marketing and distributing branded and generic medicines.

For more information, visit

Forward Looking Statements

This press release contains forward-looking statements about Devonian’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, Devonian’s ability to develop, manufacture, and successfully commercialize value-added pharmaceutical and dermo-cosmeceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Devonian to take advantage of business opportunities in the pharmaceutical and dermo-cosmeceutical industries, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations in Devonian’s prospectus dated April 21st, 2017 under the heading “Risk Factors” related to Devonian’s business. As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Dr André P. Boulet, PhD
President and Chief Executive Officer
Devonian Health Group inc.
Telephone: (514) 248-7509